The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Brief Title: A Study of Rovalpituzumab Tesirine to Study Cardiac Ventricular Repolarization in Subjects With Small Cell Lung Cancer
Official Title: An Intensive QT/QTc Study to Investigate the Effects of Rovalpituzumab Tesirine on Cardiac Ventricular Repolarization in Subjects With Small Cell Lung Cancer
Study ID: NCT02874664
Brief Summary: Study to evaluate the effect of rovalpituzumab tesirine on cardiac ventricular repolarization in subjects with small cell lung cancer (SCLC).
Detailed Description:
Minimum Age: 18 Years
Eligible Ages: ADULT, OLDER_ADULT
Sex: ALL
Healthy Volunteers: No
University of California Los Angeles, Los Angeles, California, United States
Winship Cancer Institute, Emory University, Atlanta, Georgia, United States
University of Chicago Medical Center, Chicago, Illinois, United States
Parkview Research Center, Fort Wayne, Indiana, United States
Baptist Health Lexington, Lexington, Kentucky, United States
Karmanos Cancer Institute, Detroit, Michigan, United States
Henry Ford Hospital, Detroit, Michigan, United States
Roswell Park Cancer Institute, Buffalo, New York, United States
University of Cincinnati, Cincinnati, Ohio, United States
University Hospitals Case Medical Center, Cleveland, Ohio, United States
MetroHealth Medical Center, Cleveland, Ohio, United States
Greenville Health System Cancer Institute, Greenville, South Carolina, United States
Mary Crowley Medical Research Center, Dallas, Texas, United States
Cross Cancer Institute, Edmonton, Alberta, Canada
The Ottawa Hospital-Cancer Centre, Ottawa, Ontario, Canada
Name: Daniel Da Costa, PharmD
Affiliation: AbbVie
Role: STUDY_DIRECTOR